Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Selecta Biosciences participates in a conference call with Needham » 04:55
03/26/20
03/26
04:55
03/26/20
04:55
SELB

Selecta Biosciences

$2.14 /

+0.195 (+10.03%)

Conference call with…

Conference call with management will be held on March 26 hosted by Needham.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Selecta Biosciences management to meet with Needham » 04:55
03/26/20
03/26
04:55
03/26/20
04:55
SELB

Selecta Biosciences

$2.14 /

+0.195 (+10.03%)

Meeting to be held in…

Meeting to be held in California on March 26 hosted by Needham.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Selecta Biosciences participates in a conference call with Needham » 11:42
03/24/20
03/24
11:42
03/24/20
11:42
SELB

Selecta Biosciences

$2.00 /

+0.02 (+1.01%)

Conference call with…

Conference call with management will be held on March 26 hosted by Needham.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Selecta Biosciences management to meet with Needham » 08:23
03/20/20
03/20
08:23
03/20/20
08:23
SELB

Selecta Biosciences

$1.70 /

+0.215 (+14.48%)

Meeting to be held in…

Meeting to be held in California on March 26 hosted by Needham.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Selecta COMPARE trial on track for meaningful analysis, says Mizuho » 06:49
03/20/20
03/20
06:49
03/20/20
06:49
SELB

Selecta Biosciences

$1.70 /

+0.215 (+14.48%)

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang spoke with Selecta Biosciences management regarding potential COVID-19 effects on the company's ongoing, fully-enrolled COMPARE trial as well as the scheduled Phase 3 trials for SEL-212. Despite the challenges posed by the evolving COVID-19 situation, the analyst expects the dataset from the COMPARE trial to be substantial enough for a meaningful analysis, and provide a directional conclusion. Further, management reaffirmed its plans to commence the Phase 3 trials for SEL-212 in the second half of 2020, but noted the trials may start later in 2020 than originally anticipated, Yang tells investors in a research note. The analyst keeps a Buy rating on the shares with a $7 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Selecta Biosciences expects gene threapy program in the clinic by year-end  08:04
03/12/20
03/12
08:04
03/12/20
08:04
SELB

Selecta Biosciences

$3.10 /

-0.105 (-3.28%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Selecta Biosciences plans to commence Phase 3 program of SEL-212 in 2H20  08:03
03/12/20
03/12
08:03
03/12/20
08:03
SELB

Selecta Biosciences

$3.10 /

-0.105 (-3.28%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Selecta Biosciences expects results from COMPARE trial in 3Q20  08:03
03/12/20
03/12
08:03
03/12/20
08:03
SELB

Selecta Biosciences

$3.10 /

-0.105 (-3.28%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Selecta Biosciences expects cash to meet operating requirements into 1Q21 » 08:02
03/12/20
03/12
08:02
03/12/20
08:02
SELB

Selecta Biosciences

$3.10 /

-0.105 (-3.28%)

Selecta had $91.6 million…

Selecta had $91.6 million in cash, cash equivalents, and restricted cash as of December 31, 2019, which compares to cash, cash equivalents, restricted cash, and short-term investments of $35.9 million as of September 30, 2019. Selecta believes its available cash, cash equivalents, and restricted cash will be sufficient to meet its operating requirements into the first quarter of 2021.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Selecta Biosciences reports Q4 EPS (28c), consensus (21c) » 08:02
03/12/20
03/12
08:02
03/12/20
08:02
SELB

Selecta Biosciences

$3.10 /

-0.105 (-3.28%)

"2019 was a pivotal…

"2019 was a pivotal year for Selecta. We made substantial clinical advancements, as we completed enrollment in the head-to-head COMPARE trial for our lead product candidate, SEL-212, in chronic refractory gout, and advanced our gene therapy program through strategic partnerships with AskBio. We also strengthened our organization with the addition of several key members to the executive team and welcomed a new Chairman of our Board of Directors, and completed a $70 million financing," said Carsten Brunn, Ph.D., President and CEO of Selecta. "In the coming year, we look forward to reporting topline data from the COMPARE study, commencing the Phase 3 clinical program of SEL-212, and advancing our gene therapy program into the clinic in partnership with AskBio."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.